DiaMedica Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

DMAC Stock

USD 3.17 0.16 5.32%

DiaMedica Therapeutics financial indicator trend analysis is much more than just examining DiaMedica Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DiaMedica Therapeutics is a good investment. Please check the relationship between DiaMedica Therapeutics Current Deferred Revenue and its Common Stock Shares Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DiaMedica Therapeutics Current Deferred Revenue account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have very week relationship.

The correlation between DiaMedica Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding is 0.2. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of DiaMedica Therapeutics, assuming nothing else is changed. The correlation between historical values of DiaMedica Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of DiaMedica Therapeutics are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Current Deferred Revenue i.e., DiaMedica Therapeutics' Current Deferred Revenue and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from DiaMedica Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 92.8 M, whereas Issuance Of Capital Stock is forecasted to decline to about 22.7 M.

	2023	2024 (projected)
Reconciled Depreciation	28K	21.7K
Interest Income	44.9K	47.1K

Reconciled Depreciation Interest Income

DiaMedica Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Current Assets	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		-0.27	0.81	0.78	1.0	0.83	-0.36	-0.92	0.18	0.34	-0.06	-0.38	1.0	0.34	0.96	0.97	0.78	0.88	1.0	-0.09	0.75	0.99	0.83	0.92	0.24	-0.22
Short Long Term Debt Total	-0.27		-0.07	0.0	-0.28	-0.1	0.46	0.19	0.19	-0.46	0.4	0.34	-0.28	-0.51	-0.23	-0.22	0.04	-0.12	-0.29	-0.04	-0.15	-0.29	-0.06	-0.48	0.15	0.86
Other Current Liab	0.81	-0.07		0.87	0.8	0.84	-0.26	-0.82	0.12	0.24	-0.14	-0.09	0.81	0.4	0.85	0.89	0.86	0.87	0.81	-0.32	0.73	0.81	0.86	0.78	0.4	0.02
Total Current Liabilities	0.78	0.0	0.87		0.76	0.8	-0.16	-0.79	0.54	0.14	-0.3	-0.03	0.79	0.23	0.81	0.84	0.99	0.82	0.79	-0.13	0.71	0.78	0.81	0.72	0.39	0.11
Total Stockholder Equity	1.0	-0.28	0.8	0.76		0.82	-0.37	-0.92	0.16	0.35	-0.05	-0.39	1.0	0.34	0.96	0.97	0.77	0.87	1.0	-0.09	0.75	0.99	0.83	0.92	0.23	-0.24
Property Plant And Equipment Net	0.83	-0.1	0.84	0.8	0.82		-0.22	-0.89	0.15	0.21	-0.09	0.04	0.83	0.35	0.93	0.88	0.85	0.99	0.83	-0.01	0.76	0.87	0.98	0.83	0.21	0.02
Net Debt	-0.36	0.46	-0.26	-0.16	-0.37	-0.22		0.28	0.04	-1.0	0.02	0.06	-0.35	-0.72	-0.25	-0.35	-0.13	-0.21	-0.36	0.35	-0.56	-0.36	-0.17	-0.48	-0.15	0.47
Retained Earnings	-0.92	0.19	-0.82	-0.79	-0.92	-0.89	0.28		-0.18	-0.27	0.2	0.25	-0.93	-0.34	-0.97	-0.95	-0.82	-0.92	-0.93	0.06	-0.73	-0.93	-0.88	-0.9	-0.1	0.24
Accounts Payable	0.18	0.19	0.12	0.54	0.16	0.15	0.04	-0.18		-0.03	-0.24	0.06	0.19	-0.22	0.16	0.2	0.51	0.15	0.19	-0.03	0.14	0.19	0.11	0.14	0.26	0.26
Cash	0.34	-0.46	0.24	0.14	0.35	0.21	-1.0	-0.27	-0.03		-0.03	-0.06	0.33	0.71	0.24	0.33	0.12	0.19	0.34	-0.32	0.54	0.35	0.15	0.47	0.14	-0.46
Non Current Assets Total	-0.06	0.4	-0.14	-0.3	-0.05	-0.09	0.02	0.2	-0.24	-0.03		0.21	-0.11	-0.15	-0.14	-0.08	-0.29	-0.09	-0.11	-0.37	-0.04	-0.13	-0.06	-0.2	0.16	0.34
Non Currrent Assets Other	-0.38	0.34	-0.09	-0.03	-0.39	0.04	0.06	0.25	0.06	-0.06	0.21		-0.39	0.07	-0.24	-0.3	0.0	-0.03	-0.39	0.04	0.09	-0.38	0.04	-0.31	-0.06	0.36
Cash And Short Term Investments	1.0	-0.28	0.81	0.79	1.0	0.83	-0.35	-0.93	0.19	0.33	-0.11	-0.39		0.33	0.96	0.97	0.79	0.88	1.0	-0.07	0.75	0.99	0.83	0.92	0.23	-0.23
Net Receivables	0.34	-0.51	0.4	0.23	0.34	0.35	-0.72	-0.34	-0.22	0.71	-0.15	0.07	0.33		0.35	0.38	0.23	0.34	0.34	-0.18	0.48	0.32	0.33	0.54	0.17	-0.48
Common Stock Shares Outstanding	0.96	-0.23	0.85	0.81	0.96	0.93	-0.25	-0.97	0.16	0.24	-0.14	-0.24	0.96	0.35		0.97	0.84	0.96	0.96	-0.02	0.75	0.97	0.93	0.93	0.2	-0.18
Other Stockholder Equity	0.97	-0.22	0.89	0.84	0.97	0.88	-0.35	-0.95	0.2	0.33	-0.08	-0.3	0.97	0.38	0.97		0.84	0.91	0.97	-0.23	0.76	0.97	0.87	0.94	0.32	-0.19
Total Liab	0.78	0.04	0.86	0.99	0.77	0.85	-0.13	-0.82	0.51	0.12	-0.29	0.0	0.79	0.23	0.84	0.84		0.87	0.79	-0.03	0.72	0.79	0.86	0.73	0.38	0.15
Property Plant And Equipment Gross	0.88	-0.12	0.87	0.82	0.87	0.99	-0.21	-0.92	0.15	0.19	-0.09	-0.03	0.88	0.34	0.96	0.91	0.87		0.88	-0.01	0.78	0.91	0.99	0.85	0.22	-0.01
Total Current Assets	1.0	-0.29	0.81	0.79	1.0	0.83	-0.36	-0.93	0.19	0.34	-0.11	-0.39	1.0	0.34	0.96	0.97	0.79	0.88		-0.07	0.75	0.99	0.83	0.92	0.23	-0.24
Short Term Debt	-0.09	-0.04	-0.32	-0.13	-0.09	-0.01	0.35	0.06	-0.03	-0.32	-0.37	0.04	-0.07	-0.18	-0.02	-0.23	-0.03	-0.01	-0.07		-0.15	-0.05	0.0	-0.13	-0.45	0.04
Other Current Assets	0.75	-0.15	0.73	0.71	0.75	0.76	-0.56	-0.73	0.14	0.54	-0.04	0.09	0.75	0.48	0.75	0.76	0.72	0.78	0.75	-0.15		0.75	0.82	0.68	0.17	-0.1
Net Tangible Assets	0.99	-0.29	0.81	0.78	0.99	0.87	-0.36	-0.93	0.19	0.35	-0.13	-0.38	0.99	0.32	0.97	0.97	0.79	0.91	0.99	-0.05	0.75		0.86	0.93	0.22	-0.21
Property Plant Equipment	0.83	-0.06	0.86	0.81	0.83	0.98	-0.17	-0.88	0.11	0.15	-0.06	0.04	0.83	0.33	0.93	0.87	0.86	0.99	0.83	0.0	0.82	0.86		0.79	0.2	0.04
Capital Surpluse	0.92	-0.48	0.78	0.72	0.92	0.83	-0.48	-0.9	0.14	0.47	-0.2	-0.31	0.92	0.54	0.93	0.94	0.73	0.85	0.92	-0.13	0.68	0.93	0.79		0.28	-0.41
Current Deferred Revenue	0.24	0.15	0.4	0.39	0.23	0.21	-0.15	-0.1	0.26	0.14	0.16	-0.06	0.23	0.17	0.2	0.32	0.38	0.22	0.23	-0.45	0.17	0.22	0.2	0.28		0.35
Non Current Liabilities Total	-0.22	0.86	0.02	0.11	-0.24	0.02	0.47	0.24	0.26	-0.46	0.34	0.36	-0.23	-0.48	-0.18	-0.19	0.15	-0.01	-0.24	0.04	-0.1	-0.21	0.04	-0.41	0.35

Click cells to compare fundamentals

DiaMedica Therapeutics Account Relationship Matchups

DiaMedica Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Short Long Term Debt Total	178K	118K	52K	469K	400K	276.0K
Other Current Liab	1.1M	864K	966K	1.4M	1.8M	1.9M
Total Current Liabilities	1.3M	2.0M	1.5M	2.2M	2.8M	2.9M
Total Stockholder Equity	7.6M	26.0M	44.0M	31.8M	51.1M	53.6M
Property Plant And Equipment Net	217K	174K	112K	560K	485K	509.3K
Net Debt	(3.7M)	(7.3M)	(4.7M)	(4.3M)	(4.1M)	(4.4M)
Retained Earnings	(56.6M)	(68.9M)	(82.5M)	(96.2M)	(115.6M)	(109.8M)
Accounts Payable	182K	1.1M	509K	734K	926K	563.1K
Cash	3.9M	7.4M	4.7M	4.7M	4.5M	3.5M
Non Current Assets Total	217K	174K	112K	560K	485.0K	638.8K
Non Currrent Assets Other	217K	100K	(40.4M)	(1.0)	(0.9)	(0.94)
Cash And Short Term Investments	7.9M	27.5M	45.1M	33.5M	52.9M	55.5M
Net Receivables	823K	340K	130K	82K	369K	387.5K
Common Stock Shares Outstanding	12.0M	15.7M	20.8M	26.4M	32.6M	34.2M
Liabilities And Stockholders Equity	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Other Stockholder Equity	64.2M	94.9M	126.6M	128.1M	166.6M	174.9M
Total Liab	1.4M	2.1M	1.5M	2.6M	3.1M	3.3M
Property Plant And Equipment Gross	217K	174K	179K	560K	585K	614.3K
Total Current Assets	8.8M	27.9M	45.4M	33.8M	53.7M	56.4M
Accumulated Other Comprehensive Income	2K	(2K)	(51K)	(74K)	6K	5.7K
Short Term Debt	60K	65K	49K	69K	83K	70.5K
Other Current Assets	47K	64K	84K	251K	411K	431.6K
Net Tangible Assets	17.0M	7.6M	26.0M	44.0M	50.6M	53.2M
Short Term Investments	4.0M	20.1M	40.4M	28.8M	48.4M	50.8M
Property Plant Equipment	217K	74K	112K	560K	644K	676.2K
Capital Surpluse	41.0M	63.0M	64.2M	94.9M	109.2M	114.6M
Non Current Liabilities Total	118K	53K	3K	400K	317K	158.5K
Capital Lease Obligations	178K	118K	52K	469K	400K	420K
Net Invested Capital	7.6M	26.0M	44.0M	31.8M	51.1M	28.0M
Net Working Capital	7.5M	25.9M	43.9M	31.7M	50.9M	27.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:

How To Invest In DiaMedica

Details

Is DiaMedica Stock a good investment?

Details

What is DiaMedica Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Global Correlations Find global opportunities by holding instruments from different markets

Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.60)

Return On Assets

(0.30)

Return On Equity

(0.47)

The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DiaMedica Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Common Stock Shares Outstanding

DiaMedica Therapeutics fundamental ratios Correlations

DiaMedica Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

DiaMedica Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for DiaMedica Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Net Tangible Assets	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings